Alec Van Gelder: Novo Nordisk Opens Global Patient Advocacy Role for Haemoglobinopathies
Alec Van Gelder, Vice President of Corporate Affairs, Rare Disease at Novo Nordisk, shared a post on LinkedIn:
“We’re Hiring: Associate Director, Patient Advocacy – Haemoglobinopathies at Novo Nordisk Rare Disease.
With recent progress in Sickle Cell Disease marking a pivotal moment for the haemoglobinopathy community, there has never been a more important time to help shape what comes next for patients.
We are looking for a passionate and experienced Associate Director of Patient Advocacy to partner with the haemoglobinopathies community and lead our global patient advocacy work — ensuring that the voices of those living with conditions like SCD and thalassemia sit at the very heart of Novo Nordisk’s access strategy and external engagement.
If you have a passion for improving the lives of people living with sickle cell disease and thalassemia, we would love to hear from you.
Apply now and be part of the story we are writing together with the haemoglobinopathy community.”
Stay updated with Hemostasis Today.
-
Oct 3, 2026, 16:18Mira Kassouf: Reactivating An Embryonic Gene To Treat α-Thalassemia
-
Oct 3, 2026, 15:49Behnood Bikdeli: COATED_AIR Trial Design Published as Enrollment Reaches 3,000 Patients
-
Oct 3, 2026, 15:25Vanrose Panashe Nyamangodo: A Multi-Task Deep Learning Model For Malaria And Anemia
-
Oct 3, 2026, 14:52Benny Sorensen: Glanzmann’s Thrombasthenia Finally Assigned Dedicated ICD-10 Code
-
Oct 3, 2026, 14:52The Real-World Burden Of DVT In Traumatic Fractures – ISTH
-
Oct 3, 2026, 14:41How Much Do We Really Know About The Global Burden Of Venous Thromboembolism? – World Thrombosis Day
-
Oct 3, 2026, 14:35Nnadozie Gabriel C.: Understanding Hemophilia – Modern Breakthroughs and the Gap in Global Access
-
Oct 3, 2026, 14:26Björn Mulder: Differentiating PRP Formulations and Cell Counts in Knee and Ankle OA
-
Oct 3, 2026, 14:25Jorge Enrique: Personalised Strategies for Thrombosis Management in Cancer-Associated Cases